GB2606334A — Use of cannabidivarin in the treatment of seizures associated with canine epilepsy

USPTO Abstract

A cannabidivarin (CBDV) preparation for use in the treatment of seizures associated with canine epilepsy. The seizures can be tonic, clonic, tonic-clonic, atonic, myoclonic, absence, focal seizures without impairment, focal seizures with impairment, or focal seizures with secondary generalisation. The CBDV preparation can comprise greater than 95% (w/w) CBDV and not more than 1.5% (w/w) tetrahydrocannabinol (THC). The CBDV preparation can comprise greater than or equal to 95% (w/w) CBDV and less than or equal to 5% (w/w) other cannabinoids. The other cannabinoids can be tetrahydrocannabinol (THC), tetrahydrocannabivarin (THCV), cannabidiol-C1 (CBD-C1), cannabidiol (CBD), cannabidivarin acid (CBDVA) and cannabidiol-C4 (CBD-C4). The CBDV preparation can be used with one or more concomitant anti-epileptic drugs (AED). The CBDV can be isolated from cannabis plant material. The CBDV preparation can be a synthetic preparation. The CBDV preparation can be administered at a dose greater than 2.5 mg/kg/day or at a dose of either 10 mg/kg/day or 100 mg/kg/day. A further aspect of the invention is a method of treating seizures associated with canine epilepsy by administering a CBDV preparation.